Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02151981
Title AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Osimertinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.